Zanubrutinib in Patients With IgG4-Related Disease

Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

NCT04463953 ·Status: COMPLETED ·Phase: PHASE2

Zanubrutinib for HLH

NCT05320575 ·Status: COMPLETED ·Phase: PHASE3

Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections

NCT00417573 ·Status: COMPLETED ·Phase: PHASE2

Tofatib Treatment for IgG4-related Disease

NCT05625581 ·Status: RECRUITING

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

NCT07190196 ·Status: RECRUITING ·Phase: PHASE3

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

NCT02810444 ·Status: COMPLETED ·Phase: PHASE3

Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome

NCT00001145 ·Status: COMPLETED ·Phase: PHASE2

Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

NCT01178216 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment

NCT06159283 ·Status: RECRUITING ·Phase: PHASE2

Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis

NCT00005571 ·Status: COMPLETED ·Phase: PHASE2

Rituximab for Anti-cytokine Autoantibody-Associated Diseases

NCT01842386 ·Status: COMPLETED ·Phase: PHASE1

Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum

NCT00730717 ·Status: WITHDRAWN ·Phase: PHASE2

A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)

NCT02576145 ·Status: COMPLETED ·Phase: PHASE4

A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).

NCT04425538 ·Status: COMPLETED ·Phase: PHASE2

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

NCT01084252 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

NCT06991114 ·Status: RECRUITING ·Phase: PHASE2

Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus

NCT00483119 ·Status: TERMINATED ·Phase: PHASE2

Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)

NCT01148797 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis

NCT01140503 ·Status: TERMINATED ·Phase: NA

Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis

NCT00275613 ·Status: COMPLETED ·Phase: PHASE1

Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease

NCT01147042 ·Status: TERMINATED ·Phase: PHASE4

Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis

NCT07202598 ·Status: RECRUITING ·Phase: PHASE2

Rituximab in the Treatment of Patients With Bullous Pemphigoid

NCT00286325 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Clazakizumab vs. Placebo - COVID-19 Infection

NCT04494724 ·Status: UNKNOWN ·Phase: PHASE2

Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease

NCT02980263 ·Status: WITHDRAWN ·Phase: PHASE2